Supplemental Material 1. Sample construction of relevant post-marketing trials related to all 69 novel drugs both approved by the FDA and the EMA between 2005 and 2010, after exclusion of everolimus and temsirolimus.

- 8512 initially exported clinical trials
- Exclusion of clinical trials included in the FDA submission (n=546)
- 7966 clinical trials
- 1287 clinical trials that were further excluded:
  - 227 trials whose status was inadequate (withdrawn, suspended or expanded access)
  - 441 trials mistakenly exported
  - 275 trials remaining preapproval trials (detected through start date)
  - 344 redundant trials
- 6679 relevant post-marketing trials for all 69 novel drugs of study sample